In recent years, HMGB1 has highly gained the attention of fundamental and clinical researchers. It has turned out to be one of the most fascinating molecules inside the entire arsenal of proteins of the innate immune system.
HMGB1 is a nuclear protein that has the ability to attach and bend DNA. However, it can also be discharged to the extracellular surrounding, where it exerts more functions.
As soon as HMGB1 is discharged into the cytoplasm with the help of immunocompetent cells, it is involved in inflammation (damage-associated molecular pattern, DAMP) and disease pathogenesis. Moreover, HMGB1 is related to various pathologies,1 such as:
- Autoimmune diseases
- Inflammatory diseases
- Respiratory diseases
- Myocardial infarction and others
COVID-19 is a severe acute respiratory syndrome disease and might cause considerable damage to the lungs and, if involved with comorbidities, lead to death. Openly-published statistics suggest that in spite of being on ventilation, about 85% of the patients still die. A recent analysis demonstrates how HMGB1 might denote the severity of SARS-CoV-2 linked inflammation in the lungs.2
The HMGB1 assays from Tecan are used by researchers across the globe as the gold standard for HMGB1 evaluation and quantification.
The HMGB1 Express ELISA (#30164033) is the next in line highly referenced HMGB1 ELISA (#ST51011) from Tecan.
Benefits and specifications of the HMGB1 Express ELISA kit
- Reproducibility and reliability
- Extensive measuring range varies from 0.89 to 80 ng/mL
- Assay time of just 4 hours
- Can be used manually or automated on open-format ELISA processors*
- Offers quantitative determination of HMGB1 in plasma (EDTA, citrate) and human serum
- Regulatory status EU: CE**
- Can be used for clinical and preclinical studies
*The combined use of assay, process script, and instrument should be validated individually on-site by every laboratory.
**HMGB1 express ELISA may not be available in customers’ area. They can contact their local Tecan representative.
- Kang R, et al. HMGB1 in health and disease. Mol Aspects Med, 2014, 40, 1-116.
- Andersson U, et al. Extracellular HMGB1: A therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med, 2020, 26, 42. doi.org/10.1186/s10020-020-00172-4.